KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,641,262 | -5.0% | 176,953 | +19.7% | 0.00% | 0.0% |
| Q2 2023 | $5,938,001 | +4.7% | 147,785 | +11.3% | 0.00% | 0.0% |
| Q1 2023 | $5,669,194 | -11.5% | 132,768 | -0.4% | 0.00% | 0.0% |
| Q4 2022 | $6,403,563 | +39.4% | 133,352 | +9.2% | 0.00% | 0.0% |
| Q3 2022 | $4,595,000 | +62.7% | 122,116 | +19.5% | 0.00% | +100.0% |
| Q2 2022 | $2,824,000 | -48.5% | 102,175 | +1.4% | 0.00% | -50.0% |
| Q1 2022 | $5,479,000 | -4.8% | 100,740 | +2.4% | 0.00% | 0.0% |
| Q4 2021 | $5,754,000 | +47.6% | 98,336 | -0.2% | 0.00% | +100.0% |
| Q3 2021 | $3,899,000 | +16.8% | 98,544 | +25.4% | 0.00% | 0.0% |
| Q2 2021 | $3,338,000 | -7.0% | 78,584 | +34.8% | 0.00% | 0.0% |
| Q1 2021 | $3,589,000 | -8.7% | 58,310 | +4.6% | 0.00% | -50.0% |
| Q4 2020 | $3,932,000 | +132.4% | 55,733 | +27.1% | 0.00% | +100.0% |
| Q3 2020 | $1,692,000 | +3.9% | 43,849 | +1.0% | 0.00% | 0.0% |
| Q2 2020 | $1,629,000 | – | 43,407 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,382,641 | $85,102,000 | 10.19% |
| Consonance Capital Management LP | 890,209 | $54,792,000 | 5.84% |
| CHI Advisors LLC | 400,468 | $24,649,000 | 4.94% |
| Fairmount Funds Management LLC | 109,333 | $6,729,000 | 2.84% |
| VR Adviser, LLC | 372,306 | $22,915,000 | 2.49% |
| Opaleye Management Inc. | 157,500 | $9,694,000 | 1.42% |
| Darwin Global Management, Ltd. | 86,887 | $5,348,000 | 1.05% |
| Orbimed Advisors | 1,679,417 | $103,368,000 | 0.97% |
| Nantahala Capital Management | 460,372 | $28,336,000 | 0.83% |
| Eventide Asset Management | 427,414 | $26,307,000 | 0.39% |